Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Watch This Glacier Race into the Sea - 2People who talk with their hands seem more clear and persuasive – new research
- 3Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- 4Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- 5Which Breakfast Enraptures Your Taste Buds? Vote
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- Manhunt for Brown University shooter continues: FBI releases photos of suspect, announces $50K reward
- 6 Famous Urban communities for Shopping on the planet
- BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- Passenger Missing After Going Overboard Disney Cruise Ship
- Scientist turns people’s mental images into text using ‘mind-captioning’ technology
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
